Latest

LIVE May 20th, 2021 at 2:30 PM ET
In this webinar, Berkeley Lights scientists present a new platform for antibody discovery and cell line development that accelerates the identification and production of leading therapeutic molecules.

Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials.

Findings showed that Previse could predict the onset of AKI up to 48 hours in advance of onset, sooner than the standard hospital systems like XGBoost AKI prediction model and the Sequential Organ Failure Assessment (SOFA).